Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics is a pioneering biotechnology research company dedicated to developing innovative autologous stem cell therapies for neurodegenerative disorders, including ALS, MS, and Parkinson’s disease. Addressing critical unmet medical needs, Brainstorm Cell Therapeutics is committed to advancing treatment options and improving patient outcomes.

The company's proprietary NurOwn® technology transforms autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, effectively creating a living drug delivery system. With demonstrated proof-of-concept in various animal models, Brainstorm Cell Therapeutics continues to push the boundaries of regenerative medicine. The primary address of Brainstorm Cell Therapeutics is 12 Bazel Street, POB 10019, Kiryat Aryeh, Petach Tikva 49001, IL, with an additional location at 3 University Plaza Drive, Suite 320, Hackensack, NJ 07601, US.

Brainstorm Cell Therapeutics has completed clinical trials showcasing promising safety, tolerability, and efficacy signals. With ongoing clinical trials and a commitment to innovation, Brainstorm Cell Therapeutics remains at the forefront of stem cell therapy research. We invite the management of Brainstorm Cell Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial reach.